BACKGROUND AND PURPOSE: PPARγ agonists [thiazolidinediones (TZDs)] are known to exert anti-fibrotic effects in the kidney. In addition, we previously demonstrated that sphingosine kinase 1 (SK-1) and intracellular sphingosine-1-phosphate (S1P), by reducing the expression of connective tissue growth factor (CTGF), have a protective role in the fibrotic process. EXPERIMENTAL APPROACH: Here, we investigated the effect of TZDs on intracellular sphingolipid levels and the transcriptional regulation of SK-1 in mesangial cells to evaluate potential novel aspects of the anti-fibrotic capacity of TZDs. KEY RESULTS: Stimulation with the TZDs, troglitazone and rosiglitazone, led to increased S1P levels in rat mesangial cells. This was paralleled by increased SK-1 activity as a consequence of direct effects of the TZDs on SK-1 expression. GW-9662, a PPARγ antagonist, inhibited the stimulating effect of TZDs on SK-1 mRNA and activity levels and intracellular S1P concentrations. Furthermore, SK-1 up-regulation by TZDs was functionally coupled with lower amounts of pro-fibrotic CTGF. SK-1 inhibition with SKI II almost completely abolished this effect in a dose-dependent manner. Moreover, the CTGF lowering effect of TZDs was fully blocked in MC isolated from SK-1 deficient mice (SK-1(-/-) ) as well as in glomeruli of SK-1(-/-) mice compared with wild-type mice treated with TRO and RSG. CONCLUSION AND IMPLICATIONS: These data show that TZD-induced SK-1 up-regulation results in lower amounts of CTGF, demonstrating novel facets for the anti-fibrotic effects of this class of drugs.
BACKGROUND AND PURPOSE: PPARγ agonists [thiazolidinediones (TZDs)] are known to exert anti-fibrotic effects in the kidney. In addition, we previously demonstrated that sphingosine kinase 1 (SK-1) and intracellular sphingosine-1-phosphate (S1P), by reducing the expression of connective tissue growth factor (CTGF), have a protective role in the fibrotic process. EXPERIMENTAL APPROACH: Here, we investigated the effect of TZDs on intracellular sphingolipid levels and the transcriptional regulation of SK-1 in mesangial cells to evaluate potential novel aspects of the anti-fibrotic capacity of TZDs. KEY RESULTS: Stimulation with the TZDs, troglitazone and rosiglitazone, led to increased S1P levels in rat mesangial cells. This was paralleled by increased SK-1 activity as a consequence of direct effects of the TZDs on SK-1 expression. GW-9662, a PPARγ antagonist, inhibited the stimulating effect of TZDs on SK-1 mRNA and activity levels and intracellular S1P concentrations. Furthermore, SK-1 up-regulation by TZDs was functionally coupled with lower amounts of pro-fibrotic CTGF. SK-1 inhibition with SKI II almost completely abolished this effect in a dose-dependent manner. Moreover, the CTGF lowering effect of TZDs was fully blocked in MC isolated from SK-1 deficient mice (SK-1(-/-) ) as well as in glomeruli of SK-1(-/-) mice compared with wild-type mice treated with TRO and RSG. CONCLUSION AND IMPLICATIONS: These data show that TZD-induced SK-1 up-regulation results in lower amounts of CTGF, demonstrating novel facets for the anti-fibrotic effects of this class of drugs.
Authors: Kevin J French; John J Upson; Staci N Keller; Yan Zhuang; Jong K Yun; Charles D Smith Journal: J Pharmacol Exp Ther Date: 2006-04-21 Impact factor: 4.030
Authors: Nadja Dornhöfer; Suzanne Spong; Kevin Bennewith; Ali Salim; Stephen Klaus; Neeraja Kambham; Carol Wong; Fiona Kaper; Patrick Sutphin; Randall Nacamuli; Rendall Nacalumi; Michael Höckel; Quynh Le; Michael Longaker; George Yang; Albert Koong; Amato Giaccia Journal: Cancer Res Date: 2006-06-01 Impact factor: 12.701
Authors: Shuyu Ren; Andrea Babelova; Kristin Moreth; Cuiyan Xin; Wolfgang Eberhardt; Anke Doller; Hermann Pavenstädt; Liliana Schaefer; Josef Pfeilschifter; Andrea Huwiler Journal: Kidney Int Date: 2009-08-05 Impact factor: 10.612
Authors: Nitai C Hait; Jeremy Allegood; Michael Maceyka; Graham M Strub; Kuzhuvelil B Harikumar; Sandeep K Singh; Cheng Luo; Ronen Marmorstein; Tomasz Kordula; Sheldon Milstien; Sarah Spiegel Journal: Science Date: 2009-09-04 Impact factor: 47.728
Authors: Amandeep Bajwa; Liping Huang; Elvira Kurmaeva; Hong Ye; Krishna R Dondeti; Piotr Chroscicki; Leah S Foley; Z Ayoade Balogun; Kyle J Alexander; Hojung Park; Kevin R Lynch; Diane L Rosin; Mark D Okusa Journal: J Am Soc Nephrol Date: 2016-10-31 Impact factor: 10.121
Authors: Kate A Parham; Julia R Zebol; Katie L Tooley; Wai Y Sun; Lachlan M Moldenhauer; Michaelia P Cockshell; Briony L Gliddon; Paul A Moretti; Gabor Tigyi; Stuart M Pitson; Claudine S Bonder Journal: FASEB J Date: 2015-05-18 Impact factor: 5.191
Authors: Jia Yin Soo; Sandra Orgeig; Erin Victoria McGillick; Song Zhang; I Caroline McMillen; Janna L Morrison Journal: PLoS One Date: 2017-09-26 Impact factor: 3.240
Authors: Elena M G Diarte-Añazco; Karen Alejandra Méndez-Lara; Antonio Pérez; Núria Alonso; Francisco Blanco-Vaca; Josep Julve Journal: Int J Mol Sci Date: 2019-12-12 Impact factor: 5.923